Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Supernus Pharmaceuticals

09/05/2022 23:05

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported quarterly
adjusted earnings of 43 cents​​ per share for the quarter ended
in March. The mean expectation of three analysts for the quarter
was for earnings of 24 cents per share.
    * Revenue rose 16.5% to $152.51 million from a year ago; 
analysts
expected $150.47 million. 
    * Supernus Pharmaceuticals Inc's reported EPS for the
quarter was
43 cents​.
    * The mean earnings estimate of analysts had fallen by
about 29.4%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Supernus Pharmaceuticals Inc shares had fallen by 15.0%
this
quarter and lost 5.8% so far this year.
    * The company reported quarterly net income of $25.62
million.
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 9 at 10:05 p.m.  ​All
figures in US dollars unless otherwise stated